Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick H Lizotte

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|July 30, 2014
Stimulating antitumor immunity with nanoparticlesMee Rie Sheen, Patrick H Lizotte, Seiko Toraya-Brown, et al.
Oncoimmunology|August 2, 2014
Attenuated <i>Listeria monocytogenes</i> reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysisPatrick H Lizotte, Jason R Baird, Cynthia A Stevens, et al.
Nature|November 21, 2022
Pre-T cell receptor self-MHC sampling restricts thymocyte dedifferentiationJonathan S Duke-Cohan, Aoi Akitsu, Robert J Mallis, et al.
Frontiers in Oncology|September 23, 2021
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib StudyMark M Awad, Yvan Le Bruchec, Brian Lu, et al.
Frontiers in Oncology|June 24, 2022
Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib StudyMark M Awad, Yvan Le Bruchec, Brian Lu, et al.
JCI Insight|April 20, 2018
TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapyHeng-Jia Liu, Patrick H Lizotte, Heng Du, et al.
Cancer Research|May 25, 2013
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironmentJason R Baird, Barbara A Fox, Kiah L Sanders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2018
False-Positive Plasma Genotyping Due to Clonal HematopoiesisYuebi Hu, Bryan C Ulrich, Julianna Supplee, et al.
Nature Chemical Biology|May 26, 2021
Acute pharmacological degradation of Helios destabilizes regulatory T cellsEric S Wang, Alyssa L Verano, Radosław P Nowak, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 11, 2012
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallengeJason R Baird, Katelyn T Byrne, Patrick H Lizotte, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|July 30, 2014
Stimulating antitumor immunity with nanoparticlesMee Rie Sheen, Patrick H Lizotte, Seiko Toraya-Brown, et al.
Oncoimmunology|August 2, 2014
Attenuated <i>Listeria monocytogenes</i> reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysisPatrick H Lizotte, Jason R Baird, Cynthia A Stevens, et al.
Nature|November 21, 2022
Pre-T cell receptor self-MHC sampling restricts thymocyte dedifferentiationJonathan S Duke-Cohan, Aoi Akitsu, Robert J Mallis, et al.
Frontiers in Oncology|September 23, 2021
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib StudyMark M Awad, Yvan Le Bruchec, Brian Lu, et al.
Frontiers in Oncology|June 24, 2022
Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib StudyMark M Awad, Yvan Le Bruchec, Brian Lu, et al.
JCI Insight|April 20, 2018
TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapyHeng-Jia Liu, Patrick H Lizotte, Heng Du, et al.
Cancer Research|May 25, 2013
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironmentJason R Baird, Barbara A Fox, Kiah L Sanders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2018
False-Positive Plasma Genotyping Due to Clonal HematopoiesisYuebi Hu, Bryan C Ulrich, Julianna Supplee, et al.
Nature Chemical Biology|May 26, 2021
Acute pharmacological degradation of Helios destabilizes regulatory T cellsEric S Wang, Alyssa L Verano, Radosław P Nowak, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 11, 2012
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallengeJason R Baird, Katelyn T Byrne, Patrick H Lizotte, et al.
Pageof 4